Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study evaluating safety and effectiveness of TMX-049 in patients with progressing kidney disease due to type 2 diabetic nephropathy

Next Previous
Trial Profile

A Phase 2b Study evaluating safety and effectiveness of TMX-049 in patients with progressing kidney disease due to type 2 diabetic nephropathy

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TMX 049 (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors XORTX Therapeutics

Most Recent Events

  • 29 Apr 2019 According to a XORTX Therapeutics media release, the company expects to advance this trial in 14 months.
  • 15 Mar 2019 New trial record
  • 12 Mar 2019 According to a XORTX Therapeutics media release, the trial is planned to initiate in 2019. After signing the Letter of Intent and finalizing the trial protocol, the company will will make an initial payment to Teijin to accelerate manufacturing of a clinical supply of drug for this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top